Analyst Targets 325% Upside for This Under-the-Radar Drug Stock

SVRA stock's 200-day trendline could keep a lid on today's upside

Jun 8, 2018 at 9:00 AM
facebook twitter linkedin

Evercore ISI initiated coverage on Savara Inc (NASDAQ:SVRA) with an "outperform" rating and $40 price target -- representing expected upside of almost 325% to last night's close at $9.42. The analyst in coverage said under-the-radar SVRA stock creates a compelling opportunity in the small-cap biotech sphere, and waxed optimistic on the firm's lung infection treatment, Molgradex.

In reaction, SVRA stock has jumped 9.6% in electronic trading -- signaling its first foray into double-digit territory since late May. The security's 200-day moving average kept this recent rally short-lived, and could contain today's gains, too. Longer term, the shares are down 45% from their late-December annual high, though a familiar floor has emerged near $8.50, a region that cushioned a pullback in October.

svra stock price chart june 8

Nevertheless, analysts remain upbeat toward the shares, with 100% of those in coverage maintaining a "buy" rating. Plus, the average 12-month price target sits all the way up at $25.40.

However, there is skepticism growing among traders. Short interest jumped 9.4% in the most recent reporting period to 630,000 shares While this account for just 3% of SVRA stock's available float, it would take nearly eight sessions to cover these bearish bets, at the average pace of trading.

Bernie's Best Stock Bets for Summer 2021



Special Offers from Schaeffer's Trading Partners